A review of methods for detect human Papillomavirus infection

Virology Journal

Volumn 9, Issue 1, 2012, Pages

  Abreu, André L P ^a   Souza, Raquel P ^a   Gimenes, Fabrícia ^a   Consolaro, Marcia E L ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Biomarkers; Cervical cancer; Cervical lesions progression; Detection methods; Human Papillomavirus

Indexed keywords

MESSENGER RNA; VIRUS DNA; BIOLOGICAL MARKER;

CANCER RISK; COLORIMETRY; GENE SEQUENCE; GENOTYPE; MICROARRAY ANALYSIS; MICROPLATE COLORIMETRIC HYBRIDIZATION ASSAY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRUS INFECTION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; CLASSIFICATION; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; PAPILLOMA VIRUS; VIROLOGY;

BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIROLOGY;

EID: 84868275942     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-262     Document Type: Review

References (82)

1. Stanley M: Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010, 117(Suppl 2):5-10.
2. Faridi R, Zahra A, Khan K, Idrees M: Oncogenic potential of Papillomavirus (HPV) and its relation with cervical cancer. Virol J 2011, 8:269.
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur H: Classification of papillomaviruses. Virology 2004, 324:17-27.
4. IARC: Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007, 90:1-636.
5. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al: WHO International Agency for WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens- Part B: biological agents. Lancet Oncol 2009, 10:321-322.
6. Khan S, Jaffer NN, Khan MN, Rai MA, Shafiq M, Ali A, et al: Human papillomavirus subtype 16 is common in Pakistaniwomen with cervical carcinoma. Int J Infect Dis 2007, 11:313-317.
7. Sheng J, Zhang WY: Identification of biomarkers for cervical cancer in peripheral blood lymphocytes using oligonucleotide microarrays. Chin Med J 2010, 123:1000-1005.
8. Termini L, Villa LL: Biomarkers in screening of Cervical Cancer. J Bras Doenças Sex Trasm 2008, 20:125-131.
9. Wentzensen N, Klug SJ: Cervical cancer control in the era of HPV vaccination and novel biomarkers. Pathobiology 2009, 76:82-89.
10. Chow LT, Broker TR, Steinberg BM: The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010, 118:422-449.
11. Villa LL, Denny L: Methods for detection of HPV infection and its clinical utility. Int J Gyn Obst 2006, 94:71-80.
12. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26:29-41.
13. Pannier-Stockman C, Segard C, Bennamar S, Gondry J, Boulanger JC, Sevestre H, et al: Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities. J Clin Virol 2008, 42:353-360.
14. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical human Papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-1799.
15. Forinash AB, Yancey AM, Pitlick JM, Myles TD: Safety of the HPV bivalent and quadrivalent vaccines during pregnancy (february). Ann Pharmacother 2011, 45:258-262.
16. Merck: Broad spectrum HPV (Human Papillomavirus) vaccine study in 16-to 26- Year-Old Women (V503-001).;. http://clinicaltrials.gov/ct2/show/ NCT00543543. Acessed in March 20, 2011.
17. Porras C, Bennett C, Safaeian M, Coseo S, Rodríguez AC, González P, et al: Costa Rica HPV vaccine trial (CVT) group: determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis 2010, 10:238.
18. Shen-Gunther J, Yu X: HPV molecular assays: defining analytical and clinical performance characteristics for cervical cytology specimens. Gynecol Oncol 2011, 123:263-271.
19. Hwang SJ, Shroyer KR: Biomarkers of cervical dysplasia and carcinoma. J Oncol 2012, 507286. Epub 2011 Oct 29.
20. Bozzetti M, Nonnenmacher B, Mielzinska II, Villa L, Lorincz A, Breitenbach VV, et al: Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer. Ann Epidemiol 2000, 10:466.
21. Wright TC Jr, Schiffman M: Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003, 348:489-490.
22. Frazer IH, Leggatt GR, Mattarollo SR: Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol 2011, 29:111-138.
23. Otero-Motta AP, Ordóñez JL, González-Celador R, Rivas B, Macías M, Macías MC, et al: Prevalence of human papillomavirus genotypes in cytologic abnormalities from unvaccinated women living in north-western Spain. APMIS 2011, 119:204-215.
24. Johnson LR, Starkey CR, Palmer J, Taylor J, Stout S, Holt S, et al: A comparasion of two methods to determine the presence of high-risk HPV cervical infections. Am J Clin Pathol 2008, 130:401-408.
25. Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, et al: Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010, 118:116-122.
26. Bartholomew DA, Luff RD, Quigley NB, Curtis M, Olson MC: Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples. J Clin Virol 2011, 51:38-43.
27. Rahman M, Sasagawa T, Yamada R, Kingoro A, Ichimura H, Makinoda S: High prevalence of intermediate-risk human papillomavirus infection in uterine cervices of kenyan women infected with human immunodeficiency virus. J Med Virol 2011, 83:1988-1996.
28. Hoheisel JD: Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 2006, 7:200-210.
29. Brandstetter T, Böhmer S, Prucker O, Bissé E, zur Hausen A, Alt-Mörbe J, et al: A polymerase based DNA biochip platform for human papillomavirus genotyping. J Virol Methods 2010, 163:40-48.
30. Didelot MN, Boulle N, Damay A, Costes V, Segondy M: Comparison of the PapilloCheckW assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes. J Med Virol 2011, 83:1377-1382.
31. Pista A, Verdasca N, Oliveira A: Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. J Med Virol 2011, 83:272-276.
32. Bryant D, Rai N, Rowlands G, Hibbitts S, Jones J, Tristram A, et al: Human papillomavirus type distribution in vulval intraepithelial neoplasia determined using PapilloCheck DNA microarray. J Med Virol 2011, 83:1358-1361.
33. Schopp B, Holz B, Zago M, Stubenrauch F, Petry KU, Kjaer SK, et al: Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J Med Virol 2010, 82:605-615.
34. Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C: Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of papillomavirus in cervical and anal scraps. J Med Virol 2011, 83:1377-1382.
35. Barcellos RB, Almeida SE, Sperhacke RD, Verza M, Rosso F, Medeiros RM, et al: Evaluation of a novel microplate colorimetric hybridization genotyping assay for human papillomavirus. J Virol Methods 2011, 77:38-43.
36. Zaravinos A, Mammas IN, Sourvinos G, Spandidos DA: Molecular detection methods of human papillomavirus (HPV). Int J Biol Markers 2009, 24:215-222.
37. Camargo M, Soto-De Leon S, Sanchez R, Munoz M, Vega E, Beltran M, et al: Detection by HPV of human papillomavirus in Colombia: comparison of GP5+/6+ and MY09/11 primer sets. J Virol Methods 2011, 178:68-74.
38. Coser J, Boeira TR, Fonseca AS, Ikuta N, Lunge VR: Human papillomavirus detection and typing using a nested-PCR-RFLP assay. Braz J Infect Dis 2011, 15:467-472.
39. Carvalho NO, del Castillo DM, Perone C, Januário JN, Melo VH, Brasileiro Filho G: Comparison of HPV genotyping by type-specific PCR and sequencing. Mem Inst Oswaldo Cruz 2010, 105:73-78.
40. Nogara PR, Gimenes F, Consolaro ME: Distribution of HPV genotypes and HPV-16 and HPV-18 E2 gene disruption in South Brazilian women with cervical abnormalities. Int J Gynaecol Obstet 2012. doi:10.1016/j.ijgo.2012.01.003.
41. Maver PJ, Poljak M, Seme K, Kocjan BJ: Detection and typing of low-risk human papillomavirus genotypes HPV 6, HPV 11, HPV 42, HPV 43 and HPV 44 by polymerase chain reaction and restriction fragment length polymorphism. J Virol Methods 2010, 169:215-218.
42. Naqvi SH, Wajid S, Mitra AB: Restriction fragment length polymorphism of L1 amplificon using RSA 1 detects five different human papillomavirus types and their co-infections among women attending a gynaecological outpatient department. J Virol Methods 2004, 117:91-95.
43. Santiago E, Camacho L, Junquera ML, Vázquez F: Full HPV typing by a single restriction enzyme. J Clin Virol 2006, 37:38-46.
44. Kocjan BJ, Seme K, Poljak M: Comparison of the Abbott Real Time High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffinembedded cervical cancer specimens. J Virol Methods 2011, 175:117-119.
45. Roberts I, Ng G, Foster N, Stanley M, Herdman MT, Pett MR, et al: Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR. BMC Biotechnol 2008, 8:57.
46. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, et al: Clinical validation of the Cobas 488 HPV test for cervical screening purposes. J Clin Microbiol 2011, 49:3983-3985.
47. Mateos ML, Rodríguez-Domínguez M, Sanz I, Rubio MD, Antonio J, Chacón D: Evaluation of a prototype real-time PCR assay for the separate detection of human papillomavirus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening. Enferm Infecc Microbiol Clin 2011, 29:411-414.
48. Martínez SB, Palomares JC, Artura A, Parra M, Cabezas JL, Romo JM, et al: Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples. J Virol Methods 2012, 180:7-10.
49. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Biotechnology 1992, 24:104-108.
50. Smith LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR, et al: Fluorescence detection in automated DNA sequence analysis. Nature 1986, 321:674-679.
51. Lee LG, Connell CR, Woo SL, Cheng RD, McArdle BF, Fuller CW, et al: DNA sequencing with dye-labeled terminators and T7 DNA polymerase: effect of dyes and dNTPs on incorporation of dye-terminators and probability analysis of termination fragments. Nucleic Acids Res 1992, 20:2471-2483.
52. Novais RC, Thorstenson YR: The evolution of PyrosequencingW for microbiology: from genes to genomes. J Microbiol Methods 2011, 86:1-7.
53. van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ: Evaluation of the SPF10-Inno LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol 2006, 44:3122-3129.
54. Sukasem C, Pairoj W, Saekang N, Pombubpha H, Srichunrasami C, Pongtippan A, Junyangdikul P, Chantratita W: Molecular epidemiology of human papillomavirus genotype in women with high-grade squamous intraepithelial lesion and cervical cancer: will a quadrivalent vaccine be necessary in Thailand? J Med Virol 2011, 83:119-126.
55. Lenselink CH, de Bie RP, van Hamont D, Bakkers JM, Quint WG, Massuger LF, et al: Detection and genotyping of human papillomavirus in selfobtained cervicovaginal samples by the FTA cartridge: new possibilities for cervical screening. J Clin Microbiol 2009, 47:2564-2570.
56. Schmeink CE, Bekkers RL, Massuger LF, Melchers WJ: The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol 2011, 21:139-153.
57. Dobec M, Bannwart F, Kilgus S, Kaeppeli F, Cassinotti P: Human papillomavirus infection among women with cytological abnormalities in Switzerland investigated by an automated linear array genotyping test. J Med Virol 2011, 83:1370-1376.
58. Weaver B, Shew M, Qadadri B, Tu W, Tong Y, Denski C, et al: Low- level persistence of human papillomavirus 16 DNA in a cohort of closely followed adolescent women. J Med Virol 2011, 83:1362-1369.
59. Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
60. Rosenblatt C, Wroclawski ER, Lucon AM, Pereyra EAG: HPV in Clinical Practice. São Paulo: Atheneu; 2005:25-37.
61. Wentzensen N, von Knebel DM: Biomarkers in cervical cancer screening. Dis Markers 2007, 23:315-330.
62. Dockter J, Schroder A, Eaton B, Wang A, Sikhamsay N, Morales L, et al: Analytical characterization of the APTIMA HPV Assay. J Clin Virol 2009, 45 (Suppl 1):39-47.
63. Cuschieri K, Wentzensen N: Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008, 17:2536-2545.
64. Katzenellenbogen RA, Egelkrout EM, Vliet-Gregg P, Gewin LC, Gafken PR, Galloway DA: NFX1-123 and poly (A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6- expressing Cells. J Virol 2007, 81:3786-3796.
65. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al: hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell 1997, 90:785-795.
66. Liu X, Yuan H, Fu B, Disbrow GL, Apolinario T, Tomaic V, et al: The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem 2005, 280:10807-10816.
67. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
68. de Wilde J, Wilting SM, Meijer CJ, van de Wiel MA, Ylstra B, Snijders PJ, et al: Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer. Int J Cancer 2008, 122:877-888.
69. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL: Dynamics of HPV16 DNA load reflect the natural history of cervical HPVassociated lesions. J Clin Virol 2006, 35:270-277.
70. Hesselink AT, van Ham MA, Heideman DA, Groothuismink ZM, Rozendaal L, Berkhof J, et al: Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol 2008, 46:3215-3221.
71. Xi LF, Koutsky LA, Castle PE, Wheeler CM, Galloway DA, Mao C, et al: Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst 2009, 101:153-161.
72. Lowe B, O'Neil D, Loeffert D, Nazarenko I: Distribution of Human papillomavirus load in clinical specimens. J Virol Methods 2011, 173:150-152.
73. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, et al: High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts development incident disease. Int J Cancer 2007, 21:2787-2793.
74. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al: Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions. Int J Gynecol Cancer 2008, 18:121-127.
75. Kulmala SM, Syrjänen SM, Gyllensten UB, Shabalova IP, Petrovichev N, Tosi P, et al: Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology. J Clin Pathol 2006, 59:513-517.
76. Dos Santos Oliveira LH, Rodrigues EV, de Salles Lopes AP, Fernandez AP, Cavalcanti SM: HPV 16 detection in cervical lesions, physical state of viral DNA and changes in p53 gene. Sao Paulo Med J 2003, 121:67-71.
77. Cricca M, Venturoli S, Leo E, Costa S, Musiani M, Zerbini M: Disruption of HPV 16 and E2 genes in precancerous cervical lesions. J Virol Methods 2009, 158:180-183.
78. Gallo G, Bibbo M, Bagella L, Zamparelli A, Sanseverino F, Giovagnoli MR, Vecchione A, Giordano A: Study of viral integration of HPV-16 in young patients with LSIL. J Clin Pathol 2003, 56:532-632.
79. Ho CM, Lee BH, Chang SF, Chien TY, Huang SH, Yan CC, Cheng WF: Integration of human papillomavirus correlates with levels of viral oncogene transcripts in cervical carcinogenesis. Virus Res 2011, 161:124-130.
80. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF: Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006, 102:54-60.
81. Matovina M, Sabol I, Grubisic G, Gasperov NM, Grce M: Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. Gynecol Oncol 2009, 113:120-127.
82. Jin Y, Li JP, He D, Tang LY, Zee CS, Guo SZ, et al: Clinical significance of human telomerase RNA gene (hTERC) amplification in cervical squamous cell lesions detected by fluorescence in situ hybridization. Asian Pac J Cancer Prev 2011, 12:1167-1171.